248 related articles for article (PubMed ID: 36681680)
21. Genomic and epigenomic integrative subtypes of renal cell carcinoma in a Japanese cohort.
Fukagawa A; Hama N; Totoki Y; Nakamura H; Arai Y; Saito-Adachi M; Maeshima A; Matsui Y; Yachida S; Ushiku T; Shibata T
Nat Commun; 2023 Dec; 14(1):8383. PubMed ID: 38104198
[TBL] [Abstract][Full Text] [Related]
22. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
[TBL] [Abstract][Full Text] [Related]
24. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
25. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
26. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
27. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
Velickovic M; Delahunt B; Störkel S; Grebem SK
Cancer Res; 2001 Jun; 61(12):4815-9. PubMed ID: 11406557
[TBL] [Abstract][Full Text] [Related]
28. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
Tanaka K; Kandori S; Sakka S; Nitta S; Tanuma K; Shiga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Watanabe M; Sato TA; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34841437
[TBL] [Abstract][Full Text] [Related]
29. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of subtypes of renal cell carcinoma with contrast-enhanced ultrasonography.
Xue LY; Lu Q; Huang BJ; Li CX; Yan LX; Wang WP
Clin Hemorheol Microcirc; 2016 Oct; 63(4):361-371. PubMed ID: 26598999
[TBL] [Abstract][Full Text] [Related]
32. Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Iakymenko OA; Delma KS; Jorda M; Kryvenko ON
Int J Surg Pathol; 2021 Sep; 29(6):600-605. PubMed ID: 33764165
[No Abstract] [Full Text] [Related]
33. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.
Mai KT; Landry DC; Robertson SJ; Commons AS; Burns BF; Thijssen A; Collins J
Pathol Res Pract; 2001; 197(10):671-5. PubMed ID: 11700888
[TBL] [Abstract][Full Text] [Related]
34. Imaging Mass Spectrometry Is an Accurate Tool in Differentiating Clear Cell Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma: A Proof-of-concept Study.
Lu HC; Patterson NH; Judd AM; Reyzer ML; Sehn JK
J Histochem Cytochem; 2020 Jun; 68(6):403-411. PubMed ID: 32466698
[TBL] [Abstract][Full Text] [Related]
35. Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?
Horstmann M; Geiger LM; Vogel U; Schmid H; Hennenlotter J; Kuehs U; Merseburger AS; Kruck S; Stenzl A; Bedke J
World J Urol; 2012 Aug; 30(4):525-31. PubMed ID: 21928123
[TBL] [Abstract][Full Text] [Related]
36. The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma.
Cao H; Fang L; Chen L; Zhan J; Diao X; Liu Y; Lu C; Zhang Z; Chen Y
J Ultrasound Med; 2022 Jun; 41(6):1415-1423. PubMed ID: 34499770
[TBL] [Abstract][Full Text] [Related]
37. Combined Immunohistochemistry for the "Three 7" Markers (CK7, CD117, and Claudin-7) Is Useful in the Diagnosis of Chromophobe Renal Cell Carcinoma and for the Exclusion of Mimics: Diagnostic Experience from a Single Institution.
Zhou J; Yang X; Zhou L; Zhang P; Wang C
Dis Markers; 2019; 2019():4708154. PubMed ID: 31737127
[TBL] [Abstract][Full Text] [Related]
38. Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer.
Bocu K; Batur AF; Celik ZE; Gül M; Altıntas E; Kaynar M; Kılıç O; Akand M; Tataroglu SN; Goktas S
Urol Oncol; 2023 Jun; 41(6):297.e1-297.e9. PubMed ID: 37127479
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma.
Duong NX; Le MK; Kondo T; Mitsui T
J Cell Mol Med; 2023 Jan; 27(1):66-75. PubMed ID: 36478130
[TBL] [Abstract][Full Text] [Related]
40. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
